ATC code G
Source: Wikipedia, the free encyclopedia.
Pharmaceutical drug classification
ATC code G: Genito-urinary system and sex hormones |
---|
|
ATCvet only |
|
Other ATC codes |
ATC code G Genito-urinary system and sex hormones is a section of the
Codes for
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG.[5]
ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code G". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QG". WHO Collaborating Centre for Drug Statistics Methodology.
| |||||||||
---|---|---|---|---|---|---|---|---|---|
Arsenic compounds | |||||||||
Quinoline derivatives | |||||||||
Organic acids |
| ||||||||
Sulfonamides | |||||||||
Antifungals |
| ||||||||
Other |
|
| ||
---|---|---|
Prostaglandins and analogues |
Contraction induction
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Birth control methods | |||||||
---|---|---|---|---|---|---|---|
Related topics |
| ||||||
Long-acting reversible (LARC)contraception |
| ||||||
Sterilization |
| ||||||
Hormonal contraception |
| ||||||
Barrier Methods | |||||||
Emergency Contraception (Post-intercourse) | |||||||
Spermicides | |||||||
Behavioral |
| ||||||
Experimental |
Tocolytics/labor repressants (G02CA) | |
---|---|
β2 adrenoreceptor agonists | |
Oxytocin antagonists | |
NSAIDs | |
Calcium channel blockers | |
Myosin inhibitors |
| ||
---|---|---|
vaginal administration |
Estrogens |
| ||||
---|---|---|---|---|---|
SERDs Tooltip selective estrogen receptor downregulators) |
| ||||
Aromatase inhibitors |
| ||||
Antigonadotropins |
| ||||
Others |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Estrogen receptor modulators
- Androgens and antiandrogens
- Progestogens and antiprogestogens
- List of estrogens
|
| |||
---|---|---|---|---|
SPRMs Tooltip Selective progesterone receptor modulators | ||||
PRTooltip Progesterone receptor antagonists |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Progesterone receptor modulators
- Androgens and antiandrogens
- Estrogens and antiestrogens
- List of progestogens
|
| |||||
---|---|---|---|---|---|---|
Preparations |
(indirect)
Progonadotropins |
|
---|---|
Antigonadotropins |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Urologicals, including antispasmodics (G04B) | |
---|---|
Acidifiers | |
Urinary antispasmodics (primarily antimuscarinics) | |
Other urologicals |
For erectile dysfunction |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
For premature ejaculation |
| ||||||||||||
|
Drugs used in benign prostatic hyperplasia (G04C) | |
---|---|
5α-Reductase inhibitors | |
Alpha-1 blockers | |
Steroidal antiandrogens | |
Herbal products |
|
Others |